|
1
|
Armitage JO: The aggressive peripheral
T-cell lymphomas: 2013. Am J Hematol. 88:910–918. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Abouyabis AN, Shenoy PJ, Lechowicz MJ and
Flowers CR: Incidence and outcomes of the peripheral T-cell
lymphoma subtypes in the United States. Leuk Lymphoma.
49:2099–2107. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Anderson JR, Armitage JO and Weisenburger
DD: Epidemiology of the non-Hodgkin's lymphomas: Distributions of
the major subtypes differ by geographic locations. Non-Hodgkin's
Lymphoma Classification Project. Ann Oncol. 9:717–720. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Phillips AA, Owens C, Lee S and Bhagat G:
An update on the management of peripheral T-cell lymphoma and
emerging treatment options. J Blood Med. 2:119–129. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Swerdlow SH, Campo E, Harris NL, Jaffe ES,
Pileri SA, Stein H, Thiele J and Vardiman JW: WHO Classification of
Tumours of Haematopoietic and Lymphoid Tissues. 2:(4th). Lyon:
IARC. 2008.
|
|
6
|
Vose J, Armitage J and Weisenburger D:
International T-Cell Lymphoma Project: International peripheral
T-cell and natural killer/T-cell lymphoma study: Pathology findings
and clinical outcomes. J Clin Oncol. 26:4124–4130. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lister TA, Crowther D, Sutcliffe SB,
Glatstein E, Canellos GP, Young RC, Rosenberg SA, Coltman CA and
Tubiana M: Report of a committee convened to discuss the evaluation
and staging of patients with Hodgkin's disease: Cotswolds meeting.
J Clin Oncol. 7:1630–1636. 1989.PubMed/NCBI
|
|
8
|
The International Non-Hodgkin's Lymphoma
Prognostic Factors Project: A predictive model for aggressive
non-Hodgkin's lymphoma. N Engl J Med. 329:987–994. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
de Leval L, Gisselbrecht C and Gaulard P:
Advances in the understanding and management of angioimmunoblastic
T-cell lymphoma. Br J Haematol. 148:673–689. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mourad N, Mounier N, Brière J, Raffoux E,
Delmer A, Feller A, Meijer CJ, Emile JF, Bouabdallah R, Bosly A, et
al: Clinical, biologic, and pathologic features in 157 patients
with angioimmunoblastic T-cell lymphoma treated within the Groupe
d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood.
111:4463–4470. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Weisenburger DD, Savage KJ, Harris NL,
Gascoyne RD, Jaffe ES, MacLennan KA, Rüdiger T, Pileri S, Nakamura
S, Nathwani B, et al: International Peripheral T-cell Lymphoma
Project: Peripheral T-cell lymphoma, not otherwise specified: A
report of 340 cases from the International Peripheral T-cell
Lymphoma Project. Blood. 117:3402–3408. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Federico M, Rudiger T, Bellei M, Nathwani
BN, Luminari S, Coiffier B, Harris NL, Jaffe ES, Pileri SA, Savage
KJ, et al: Clinicopathologic characteristics of angioimmunoblastic
T-cell lymphoma: Analysis of the international peripheral T-cell
lymphoma project. J Clin Oncol. 31:240–246. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Coiffier B, Brousse N, Peuchmaur M, Berger
F, Gisselbrecht C, Bryon PA and Diebold J: Peripheral T-cell
lymphomas have a worse prognosis than B-cell lymphomas: A
prospective study of 361 immunophenotyped patients treated with the
LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives).
Ann Oncol. 1:45–50. 1990.PubMed/NCBI
|
|
14
|
Lunning MA: Treatment of peripheral T-cell
lymphoma: Many shades of gray. Oncology (Williston Park).
29:545–550. 2015.PubMed/NCBI
|
|
15
|
Kyle RA and Rajkumar SV: Multiple myeloma.
Blood. 111:2962–2972. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Richardson PG, Barlogie B, Berenson J,
Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina
M, Alexanian R, et al: A phase 2 study of bortezomib in relapsed,
refractory myeloma. N Engl J Med. 348:2609–2617. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goy A, Bernstein SH, Kahl BS, Djulbegovic
B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial
S, et al: Bortezomib in patients with relapsed or refractory mantle
cell lymphoma: Updated time-to-event analyses of the multicenter
phase 2 PINNACLE study. Ann Oncol. 20:520–525. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu S, Yuan Z, Zhang C, Fu W and Hou J:
Bortezomib-based treatment for relapsed and refractory
angioimmunoblastic T-cell lymphoma: Case report and literature
review. Oncol Lett. 4:262–264. 2012.PubMed/NCBI
|
|
19
|
Hourigan CS, Forde PM, Ambinder RF and
Gladstone DE: Bortezomib salvage therapy in refractory acute adult
T-cell leukemia/lymphoma. Leuk Lymphoma. 54:2563–2564. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wilson WH, Bryant G, Bates S, Fojo A,
Wittes RE, Steinberg SM, Kohler DR, Jaffe ES, Herdt J, Cheson BD,
et al: EPOCH chemotherapy: Toxicity and efficacy in relapsed and
refractory non-Hodgkin's lymphoma. J Clin Oncol. 11:1573–1582.
1993.PubMed/NCBI
|
|
21
|
Kim SJ, Yoon DH, Kang HJ, Kim JS, Park SK,
Kim HJ, Lee J, Ryoo BY, Ko YH, Huh J, et al: Consortium for
Improving Survival of Lymphoma (CISL) investigators: Bortezomib in
combination with CHOP as first-line treatment for patients with
stage III/IV peripheral T-cell lymphomas: A multicentre,
single-arm, phase 2 trial. Eur J Cancer. 48:3223–3231. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee J, Suh C, Kang HJ, Ryoo BY, Huh J, Ko
YH, Eom HS, Kim K, Park K and Kim WS: Phase I study of proteasome
inhibitor bortezomib plus CHOP in patients with advanced,
aggressive T-cell or NK/T-cell lymphoma. Ann Oncol. 19:2079–2083.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zinzani PL, Musuraca G, Tani M, Stefoni V,
Marchi E, Fina M, Pellegrini C, Alinari L, Derenzini E, de Vivo A,
et al: Phase II trial of proteasome inhibitor bortezomib in
patients with relapsed or refractory cutaneous T-cell lymphoma. J
Clin Oncol. 25:4293–4297. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen D, Frezza M, Schmitt S, Kanwar J and
Dou QP: Bortezomib as the first proteasome inhibitor anticancer
drug: Current status and future perspectives. Curr Cancer Drug
Targets. 11:239–253. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ri M, Iida S, Ishida T, Ito A, Yano H,
Inagaki A, Ding J, Kusumoto S, Komatsu H, Utsunomiya A and Ueda R:
Bortezomib-induced apoptosis in mature T-cell lymphoma cells
partially depends on upregulation of Noxa and functional repression
of Mcl-1. Cancer Sci. 100:341–348. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shen L, Au WY, Guo T, Wong KY, Wong ML,
Tsuchiyama J, Yuen PW, Kwong YL, Liang RH and Srivastava G:
Proteasome inhibitor bortezomib-induced apoptosis in natural killer
(NK)-cell leukemia and lymphoma: An in vitro and in vivo
preclinical evaluation. Blood. 110:469–470. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Iwata S, Yano S, Ito Y, Ushijima Y, Gotoh
K, Kawada J, Fujiwara S, Sugimoto K, Isobe Y, Nishiyama Y and
Kimura H: Bortezomib induces apoptosis in T lymphoma cells and
natural killer lymphoma cells independent of Epstein-Barr virus
infection. Int J Cancer. 129:2263–2273. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rice TW, Rodriguez RM and Light RW: The
superior vena cava syndrome: Clinical characteristics and evolving
etiology. Medicine (Baltimore). 85:37–42. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yellin A, Rosen A, Reichert N and
Lieberman Y: Superior vena cava syndrome. The myth - the facts. Am
Rev Respir Dis. 141:1114–1118. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Chee CE, Bjarnason H and Prasad A:
Superior vena cava syndrome: An increasingly frequent complication
of cardiac procedures. Nat Clin Pract Cardiovasc Med. 4:226–230.
2007. View Article : Google Scholar : PubMed/NCBI
|
